Cargando…

Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia

BACKGROUND: Alterations in GABAnergic system are implicated in the pathophysiology of schizophrenia. Available antipsychotics that target GABA receptor form a desirable therapeutic strategy in the treatment regimen of schizophrenia, unfortunately, suffer serious setback due to their prolonged side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Marunnan, Sahila Mohammed, Pulikkal, Babitha Pallikkara, Jabamalairaj, Anitha, Bandaru, Srinivas, Yadav, Mukesh, Nayarisseri, Anuraj, Doss, Victor Arokia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725540/
https://www.ncbi.nlm.nih.gov/pubmed/27919211
http://dx.doi.org/10.2174/1567201814666161205131745
_version_ 1783285547751440384
author Marunnan, Sahila Mohammed
Pulikkal, Babitha Pallikkara
Jabamalairaj, Anitha
Bandaru, Srinivas
Yadav, Mukesh
Nayarisseri, Anuraj
Doss, Victor Arokia
author_facet Marunnan, Sahila Mohammed
Pulikkal, Babitha Pallikkara
Jabamalairaj, Anitha
Bandaru, Srinivas
Yadav, Mukesh
Nayarisseri, Anuraj
Doss, Victor Arokia
author_sort Marunnan, Sahila Mohammed
collection PubMed
description BACKGROUND: Alterations in GABAnergic system are implicated in the pathophysiology of schizophrenia. Available antipsychotics that target GABA receptor form a desirable therapeutic strategy in the treatment regimen of schizophrenia, unfortunately, suffer serious setback due to their prolonged side effects. The present investigation focuses on developing QSAR models from the biological activity of herbal compounds and their derivatives that promise to be alternative candidates to GABA uptake inhibitors. METHODS: Three sets of compounds were undertaken in the study to develop QSAR models. The first set consisted of nine compounds which included Magnolol, Honokiol and other GABA acting established compounds. The second set consisted of 16 derivatives of N-diarylalkenyl-piperidinecarboxylic acid. The third QSAR dataset was made up of thirty two compounds which were Magnolol and Honokiol derivatives. Multiple linear regressions (MLR) and support vector machine (SVM) supervised quantitative structure-activity relationship (QSAR) models were developed to predict the biological activity of these three sets. The purpose of taking three QSAR sets of diverse chemical structures but identical in their GABA targeting and pharmacological action was to identify common chemical structure features responsible for structure-activity relationship (SAR). RESULTS: Linear and non-linear QSAR models confirmed that the three sets shared common structural descriptors derived from WHIM (Weighted Holistic Invariant Molecular descriptors), 3D-MoRSE and Eigenvalue classes. CONCLUSION: It was concluded that properties like electro negativity and polarizability play a crucial role in controlling the activity of herbal compounds against GABA receptor.
format Online
Article
Text
id pubmed-5725540
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-57255402018-05-01 Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia Marunnan, Sahila Mohammed Pulikkal, Babitha Pallikkara Jabamalairaj, Anitha Bandaru, Srinivas Yadav, Mukesh Nayarisseri, Anuraj Doss, Victor Arokia Curr Neuropharmacol Article BACKGROUND: Alterations in GABAnergic system are implicated in the pathophysiology of schizophrenia. Available antipsychotics that target GABA receptor form a desirable therapeutic strategy in the treatment regimen of schizophrenia, unfortunately, suffer serious setback due to their prolonged side effects. The present investigation focuses on developing QSAR models from the biological activity of herbal compounds and their derivatives that promise to be alternative candidates to GABA uptake inhibitors. METHODS: Three sets of compounds were undertaken in the study to develop QSAR models. The first set consisted of nine compounds which included Magnolol, Honokiol and other GABA acting established compounds. The second set consisted of 16 derivatives of N-diarylalkenyl-piperidinecarboxylic acid. The third QSAR dataset was made up of thirty two compounds which were Magnolol and Honokiol derivatives. Multiple linear regressions (MLR) and support vector machine (SVM) supervised quantitative structure-activity relationship (QSAR) models were developed to predict the biological activity of these three sets. The purpose of taking three QSAR sets of diverse chemical structures but identical in their GABA targeting and pharmacological action was to identify common chemical structure features responsible for structure-activity relationship (SAR). RESULTS: Linear and non-linear QSAR models confirmed that the three sets shared common structural descriptors derived from WHIM (Weighted Holistic Invariant Molecular descriptors), 3D-MoRSE and Eigenvalue classes. CONCLUSION: It was concluded that properties like electro negativity and polarizability play a crucial role in controlling the activity of herbal compounds against GABA receptor. Bentham Science Publishers 2017-11 2017-11 /pmc/articles/PMC5725540/ /pubmed/27919211 http://dx.doi.org/10.2174/1567201814666161205131745 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Marunnan, Sahila Mohammed
Pulikkal, Babitha Pallikkara
Jabamalairaj, Anitha
Bandaru, Srinivas
Yadav, Mukesh
Nayarisseri, Anuraj
Doss, Victor Arokia
Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title_full Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title_fullStr Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title_full_unstemmed Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title_short Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
title_sort development of mlr and svm aided qsar models to identify common sar of gaba uptake herbal inhibitors used in the treatment of schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725540/
https://www.ncbi.nlm.nih.gov/pubmed/27919211
http://dx.doi.org/10.2174/1567201814666161205131745
work_keys_str_mv AT marunnansahilamohammed developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT pulikkalbabithapallikkara developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT jabamalairajanitha developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT bandarusrinivas developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT yadavmukesh developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT nayarisserianuraj developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia
AT dossvictorarokia developmentofmlrandsvmaidedqsarmodelstoidentifycommonsarofgabauptakeherbalinhibitorsusedinthetreatmentofschizophrenia